Blood-borne viruses and their survival in the environment: Is public concern about community needlestick exposures justified?

Australian and New Zealand Journal of Public Health

Volumn 27, Issue 6, 2003, Pages 602-607

  Thompson, Sandra C ^a,b   Boughton, Clem R ^b,c   Dore, Gregory J ^b,d  

^a DEPARTMENT OF HEALTH   (Australia)

^b Viral Hepat Prev Board (Australia)   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; INTERFERON; VIRUS VACCINE;

AUSTRALIA; BLOOD VOLUME; COMMUNICABLE DISEASE; DRUG USE; ENVIRONMENTAL TEMPERATURE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMIDITY; MEDICAL DOCUMENTATION; MEDLINE; NEEDLE; NEEDLESTICK INJURY; NONHUMAN; PROPHYLAXIS; PUBLIC HEALTH; PUBLISHING; REVIEW; ROOM TEMPERATURE; SUN EXPOSURE; VACCINATION; VIRUS SURVIVAL; VIRUS TRANSMISSION;

EID: 0346340795     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2003.tb00606.x     Document Type: Review

References (53)

1. Cossart YE. Epidemiology of serum hepatitis. Br Med Bull 1972;28:156-62.
2. Blacker P, Tindall B, Wodak A, Cooper D. Exposure of intravenous drug users to AIDS retrovirus, Sydney, 1985. Aust N Z J Med 1986;16:686-90.
3. Gust I, Nicholson S, Dimitrakakis M, Hoy J, Lucas R. Prevalence of infection with hepatitis C virus in Australia. Med J Aust 1989;151:719.
4. Wolk J, Wodak A, Morlet A, Guinan JJ, Wilson E, Gold J, Cooper DA. Syringe HIV seroprevalence and behavioural and demographic characteristics of intravenous drug users in Sydney, Australia, 1987. AIDS 1988;2:373-7.
5. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997;349:1797-800.
6. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, Viral Hepatitis, and Sexually Transmissible Infections in Australia Annual Surveillance Report 2002. Sydney (NSW): The University of New South Wales; 2002.
7. Crofts N, Aitken CK, Kaldor JM. The force of numbers: Why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999;10:220-1.
8. Moaven LD, Crofts N, Locarnini SA. Hepatitis C virus infection in Victorian injecting drug users in 1971. Med J Aust 1993;158:574.
9. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003;23:717-24.
10. Health Outcomes International. Return on Investment in Needle and Syringe Programs in Australia. Canberra: Population Health Division, Australian Government Department of Health and Ageing, 2002 October.
11. Kelsall J, Lloyd S, Kerger M, Crofts N. AIVL National Injecting Equipment Disposal Study. Canberra: Australian Injecting and Illicit Users League; 2002 August.
12. Crofts N, Hopper JL, Milner R, Breschkin AM, Bowden DS, Locarnini SA. Blood-borne virus infections among Australian injecting drug users: Implications for spread of HIV. Eur J Epidemiol 1994;10:687-94.
13. Petersen NJ, Barret DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976;32:572-4.
14. Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977;136:571-6.
15. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B after drying and storage for one week. Lancet 1981;1:550-1.
16. Favero MS, Bond WW, Petersen NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis 1974;129:210-2.
17. Struve J. Hepatitis B infection among Swedish adults: Aspects on seroepidemiology, transmission and vaccine response. Scand J Infect Dis 1992; 82 Suppl:1-57.
18. Beasley RP, Hwang L-Y. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983;147:185-90.
19. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1(8643):889-93.
20. Akbar N, Basuki B, Mulyanto, Garabrant DH, Sulaiman A, Noer HM. Ethnicity, socioeconomic status, transfusions and risk of hepatitis B and hepatitis C infection. J Gastroenterol Hepatol 1997;12:752-7.
21. Goh KT, Ding JL, Monteiro EH, Oon CJ. Hepatitis B infection in households of acute cases. J Epidemiol Community Health 1985;39:123-8.
22. Heimer R, Khoshnood K, Jariwala-Freeman B, Duncan B, Harima Y. Hepatitis in used syringes: The limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis 1996;173:997-1000.
23. Krajden M, Comanor C, Rifkin O, Grigoriew A, Minor JM, Kapke GF. Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay. J Clin Microbiol 1998;36;382-6.
24. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
25. Dore GJ, Law M, MacDonald M, Kaldor J. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171-84.
26. Crofts N, Jolley D, Kaldor J, Van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997;51:692-7.
27. Rodger AJ, Thomson J, Thompson S, Crofts N, Jolley D,Lanigan A, et al. Assessment of long term effects of chronic hepatitis C infection - A pilot. J Gastroenterol Hepatol 1999;14:269-73.
28. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: Rates, routes, and cofactors. Epidemiol Rev 1996;18:137-48.
29. Dore GJ, Law MG, Kaldor JM. Prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999;341:2093-4.
30. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, et al. Mother-to-child transmission of hepatitis C virus: Evidence for preventable peripartum transmission. Lancet 2000;356:904-7.
31. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. Br Med J 1997;315:333-7.
32. Polywka S, Schroter M, Feucht HH, Zollner B, Laufs R. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin Infect Dis 1999;29:1327-9.
33. Deva AK, Vickery K, Zou J, West RH, Selby W, Benn RA, Harris JP, Cossart YE. Detection of persistent vegetative bacteria and amplified viral nucleic acid from in-use testing of gastrointestinal endoscopes. J Hosp Infect 1998;39:149-57.
34. Charrel RN, De Chesse R, Decaudin A, De Micco P, De Lamballerie X. Evaluation of disinfectant efficacy against hepatitis C virus using a RT-PCR-based method. J Hosp Infect 2001;49(2):129-34.
35. Cardoso MS, Koerner K, Hinz W, Lenz C, Schwandt A, Kubanek, B. Hepatitis C virus stability: The issue! Vox Sang 1999;76:124-7.
36. Damen M, Sillekens P, Sjerps M, Melsert R, Frantzen I, Reesink HW, et al. Stability of hepatitis C virus RNA during specimen handling and storage prior to NASBA amplification. J Virol Methods 1998;72:175-84.
37. Halfon P, Khiri H, Gerolami V, Bouliere M, Feryn JM, Reynier P, et al. Impact of various handling and storage conditions on quantitative detection of hepatitis C RNA. J Hepatol 1996;25:307-11.
38. Abe K, Konomi N. Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. J Clin Micro 1998;36:3070-2.
39. Piazza M, Borgia G, Picciotto L, Cicciarello S, Nappa S. HCV-RNA survival as detected by PCR in the environment. J Biol Res 1994;70:167-70.
40. Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: Molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994;43:415-9.
41. Allander T, Gruber A, Naghavi M, Beyene A, Soderstrom T, Bjorkholm M, et al. Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet 1995;345:603-7.
42. Weber DJ, Rutala WA. The emerging nosocomial pathogens Cryptosporidium, Escherichia coli O157:H7, Helicobacter pylori, and hepatitis C: Epidemiology, environmental survival, efficacy of disinfection, and control measures. Infect Control Hosp Epidemiol 2001;22:306-15.
43. Crofts N. Hepatitis C infection among injecting drug users: Where do we go from here? Drug Alcohol Rev 1994;13:235-7.
44. Crofts N, Aitken C. Risk behaviours for and incidence of blood-borne viruses in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997;167:17-20.
45. Van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C among injecting drug users in a prevention setting: Retrospective cohort study. Br Med J 1998;317:433-7.
46. MacDonald MA, Wodak AD, Dolan KA, Van Beek I, Cunningham PH, Kaldor JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust 2000;172:57-61.
47. Van Bueren J, Simpson RA, Jacobs P, Cookson BD. Survival of human immunodeficiency virus in suspension and dried onto surfaces. J Clin Microbiol 1994;32:571-4.
48. Tjotta E, Hungnes O, Grinde B. Survival of HIV-1 activity after disinfection, temperature and pH changes, or drying. J Med Virol 1991;35:223-7.
49. Heimer R, Abdala N. Viability of HIV-1 in syringes: Implications for interventions among injection drug users. AIDS Read 2000;10:410-7.
50. Abdala N, Stephens PC, Griffith BP, Heimer R. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:73-80.
51. Abdala N, Reyes R, Carney JM, Heimer R. Survival of HIV-1 in syringes: Effects of temperature during storage. Subst Use Misuse 2000;35:1369-83.
52. Crofts N, Hopper JL, Milner R, Breschkin AM, Bowden DS, Locarnini SA. Blood-borne virus infections among Australian injecting drug users: Implications for spread of HIV. Eur J Epidemiol 1994:10:187-694.
53. Jaeckal E, Cornberg M, Wedmeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.